Poznámky k epizodě
A quiet week for acromegaly, with no top-tier-journal papers and only incremental observational work (tumor size drives headache; surgical remission isn't predicted by tumor subtype), while rare disease industry news was dominated by an FDA draft framework for "plug and play" gene therapies and a fresh $90M launch in Charcot-Marie-Tooth.

